Drug firms Wockhardt, Cadila Healthcare and Hospira are voluntarily recalling certain lots of drugs in the U.S., according to the U.S. Food and Drug Administration (USFDA).
As per the information available on the USFDA website, Wockhardt USA Inc., the U.S.-based arm of the company, is recalling 11.18 lakh Metoprolol Succinate extended-release tablets, a hypertension drug, for ‘failed dissolution specifications.’ The tablets were manufactured by Mumbai-based Wockhardt, and distributed by Wockhardt USA LLC.
The nation-wide recall was initiated by the company on April 17 this year and initiated under Class-III which FDA defined as “a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.”
Zydus Pharmaceuticals USA Inc, the U.S.-based arm of Ahmedabad-based Cadila Healthcare, is recalling 58,920 bottles of Benzonatate Capsules, used to treat coughs, due to “wet and/or leaking capsules.”
The recall has been initiated by the company on November 26 under Class-II, which FDA states as a situation in which use of or exposure to a violative product might cause temporary or medically reversible adverse health consequences.
The capsules were manufactured by Ahmedabad-based Cadila Healthcare and distributed by Zydus Pharmaceuticals USA.
Further, Hospira was recalling 2.62 lakh vials of Meropenem, an antibiotic, in the U.S, Puerto Rico, Italy, Netherlands and Spain for having “defective container”.
The vials were manufactured by Hospira Healthcare India for Hospira, Inc. The recall was initiated by the company on October 24 and under Class-II.
Comments from the companies could not be obtained immediately.
